Mineralys Therapeutics, Inc. Profile Avatar - Palmy Investing

Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administ…

Biotechnology
US, Radnor [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Mineralys Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of MLYS's Analysis
CIK: 1933414 CUSIP: 603170101 ISIN: US6031701013 LEI: - UEI: -
Secondary Listings
MLYS has no secondary listings inside our databases.